From sphingosine kinase to dihydroceramide desaturase: a structure-activity relationship (SAR) study of the enzyme inhibitory and anticancer activity of 4-((4-(4-chlorophenyl)thiazol-2-yl)amino)phenol (SKI-II)

Luigi Aurelio, Carmen V. Scullino, Melissa R. Pitman, Anna E Sexton, Victoria Oliver, Lorena Davies, Richard J. Rebello, Luc Furic, Darren J Creek, Stuart M. Pitson, Bernard L. Flynn

Research output: Contribution to journalArticleResearchpeer-review

Abstract

The sphingosine kinase (SK) inhibitor, SKI-II, has been employed extensively in biological investigations of the role of SK1 and SK2 in disease and has demonstrated impressive anticancer activity in vitro and in vivo. However, interpretations of results using this pharmacological agent are complicated by several factors: poor SK1/2 selectivity, additional activity as an inducer of SK1-degradation, and off-target effects, including its recently identified capacity to inhibit dihydroceramide desaturase-1 (Des1). In this study, we have delineated the structure-activity relationship (SAR) for these different targets and correlated them to that required for anticancer activity and determined that Des1 inhibition is primarily responsible for the antiproliferative effects of SKI-II and its analogues. In the course of these efforts, a series of novel SK1, SK2, and Des1 inhibitors have been generated, including compounds with significantly greater anticancer activity.
Original languageEnglish
Pages (from-to)965-984
Number of pages20
JournalJournal of Medicinal Chemistry
Volume59
Issue number3
DOIs
Publication statusPublished - 11 Feb 2016

Cite this

Aurelio, Luigi ; Scullino, Carmen V. ; Pitman, Melissa R. ; Sexton, Anna E ; Oliver, Victoria ; Davies, Lorena ; Rebello, Richard J. ; Furic, Luc ; Creek, Darren J ; Pitson, Stuart M. ; Flynn, Bernard L. / From sphingosine kinase to dihydroceramide desaturase : a structure-activity relationship (SAR) study of the enzyme inhibitory and anticancer activity of 4-((4-(4-chlorophenyl)thiazol-2-yl)amino)phenol (SKI-II). In: Journal of Medicinal Chemistry. 2016 ; Vol. 59, No. 3. pp. 965-984.
@article{b9da3a1e784a4ab7becae4f88f9e3f92,
title = "From sphingosine kinase to dihydroceramide desaturase: a structure-activity relationship (SAR) study of the enzyme inhibitory and anticancer activity of 4-((4-(4-chlorophenyl)thiazol-2-yl)amino)phenol (SKI-II)",
abstract = "The sphingosine kinase (SK) inhibitor, SKI-II, has been employed extensively in biological investigations of the role of SK1 and SK2 in disease and has demonstrated impressive anticancer activity in vitro and in vivo. However, interpretations of results using this pharmacological agent are complicated by several factors: poor SK1/2 selectivity, additional activity as an inducer of SK1-degradation, and off-target effects, including its recently identified capacity to inhibit dihydroceramide desaturase-1 (Des1). In this study, we have delineated the structure-activity relationship (SAR) for these different targets and correlated them to that required for anticancer activity and determined that Des1 inhibition is primarily responsible for the antiproliferative effects of SKI-II and its analogues. In the course of these efforts, a series of novel SK1, SK2, and Des1 inhibitors have been generated, including compounds with significantly greater anticancer activity.",
author = "Luigi Aurelio and Scullino, {Carmen V.} and Pitman, {Melissa R.} and Sexton, {Anna E} and Victoria Oliver and Lorena Davies and Rebello, {Richard J.} and Luc Furic and Creek, {Darren J} and Pitson, {Stuart M.} and Flynn, {Bernard L.}",
year = "2016",
month = "2",
day = "11",
doi = "10.1021/acs.jmedchem.5b01439",
language = "English",
volume = "59",
pages = "965--984",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "AMER CHEMICAL SOC",
number = "3",

}

From sphingosine kinase to dihydroceramide desaturase : a structure-activity relationship (SAR) study of the enzyme inhibitory and anticancer activity of 4-((4-(4-chlorophenyl)thiazol-2-yl)amino)phenol (SKI-II). / Aurelio, Luigi; Scullino, Carmen V.; Pitman, Melissa R.; Sexton, Anna E; Oliver, Victoria; Davies, Lorena; Rebello, Richard J.; Furic, Luc; Creek, Darren J; Pitson, Stuart M.; Flynn, Bernard L.

In: Journal of Medicinal Chemistry, Vol. 59, No. 3, 11.02.2016, p. 965-984.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - From sphingosine kinase to dihydroceramide desaturase

T2 - a structure-activity relationship (SAR) study of the enzyme inhibitory and anticancer activity of 4-((4-(4-chlorophenyl)thiazol-2-yl)amino)phenol (SKI-II)

AU - Aurelio, Luigi

AU - Scullino, Carmen V.

AU - Pitman, Melissa R.

AU - Sexton, Anna E

AU - Oliver, Victoria

AU - Davies, Lorena

AU - Rebello, Richard J.

AU - Furic, Luc

AU - Creek, Darren J

AU - Pitson, Stuart M.

AU - Flynn, Bernard L.

PY - 2016/2/11

Y1 - 2016/2/11

N2 - The sphingosine kinase (SK) inhibitor, SKI-II, has been employed extensively in biological investigations of the role of SK1 and SK2 in disease and has demonstrated impressive anticancer activity in vitro and in vivo. However, interpretations of results using this pharmacological agent are complicated by several factors: poor SK1/2 selectivity, additional activity as an inducer of SK1-degradation, and off-target effects, including its recently identified capacity to inhibit dihydroceramide desaturase-1 (Des1). In this study, we have delineated the structure-activity relationship (SAR) for these different targets and correlated them to that required for anticancer activity and determined that Des1 inhibition is primarily responsible for the antiproliferative effects of SKI-II and its analogues. In the course of these efforts, a series of novel SK1, SK2, and Des1 inhibitors have been generated, including compounds with significantly greater anticancer activity.

AB - The sphingosine kinase (SK) inhibitor, SKI-II, has been employed extensively in biological investigations of the role of SK1 and SK2 in disease and has demonstrated impressive anticancer activity in vitro and in vivo. However, interpretations of results using this pharmacological agent are complicated by several factors: poor SK1/2 selectivity, additional activity as an inducer of SK1-degradation, and off-target effects, including its recently identified capacity to inhibit dihydroceramide desaturase-1 (Des1). In this study, we have delineated the structure-activity relationship (SAR) for these different targets and correlated them to that required for anticancer activity and determined that Des1 inhibition is primarily responsible for the antiproliferative effects of SKI-II and its analogues. In the course of these efforts, a series of novel SK1, SK2, and Des1 inhibitors have been generated, including compounds with significantly greater anticancer activity.

UR - http://www.scopus.com/inward/record.url?scp=84958167631&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.5b01439

DO - 10.1021/acs.jmedchem.5b01439

M3 - Article

VL - 59

SP - 965

EP - 984

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 3

ER -